Ratio-Ipratropium UDV · DIN 02097168 · 250 mcg/mL · Inh Sol-2mL UDV Pk
Limited Use, Reason for Use code 265, 266, 267, 268 required; Health Canada lists this DIN as Cancelled post market since 2018-05-18 — choose a marketed DIN from the same-category list.Discontinued May 18, 2018 · checked November 19, 2026
StatusLimited Use, Reason for Use code 265, 266, 267, 268 required; Health Canada lists this DIN as Cancelled post market since 2018-05-18 — choose a marketed DIN from the same-category list.
Write on scriptone applicable Reason for Use code, 265 or 266 or 267 or 268 (criteria below); Health Canada lists this DIN as Cancelled post market since 2018-05-18 — choose a marketed DIN from the same-category list.
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays:
• ODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
• Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 265, 266, 267, 268
Coverage limit:
For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.
Reason for Use code 265
Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have a tracheostomy;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 266
Individuals must have a known hypersensitivity to the preservative in the bulk solution, and be patients with cystic fibrosis in whom nebulizer therapy is indicated;.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 267
Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have severe mental or physical disabilities;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 268
Patients who have previously used nebulizer therapy within the last 12 month period.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Ratio-Ipratropium UDV · DIN 02097168
Manufacturer: Ratiopharm Inc.; listing date 1996-12-19
Health Canada: Cancelled post market since 2018-05-18 · brand RATIO-IPRATROPIUM UDV · ATC R03BB01 IPRATROPIUM BROMIDE · form Solution · route Inhalation · ingredients IPRATROPIUM BROMIDE 250 MCG/ML · company Teva canada limited · schedule Prescription
Ratio-Ipratropium UDV: Formulary list price $1.32 per unit (the source does not state the unit; exact figure $1.3180). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02097168)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02097168).
DIN 02097168: Ratio-Ipratropium UDV
Raw flags: dinStatus=E, sec12=Y, sec3=Y
Item: 120800046; group id 206; item number 0376; lccId 00031; manufacturer id RPH
Source form: Inh Sol-2mL UDV Pk; strength: 250mcg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; DIN status E, meaning unconfirmed
Source prices (unrounded): $1.3180; ministry $1.3180
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02097168
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19798
Interchangeable products
Atrovent UDV · DIN 01950681 · not recorded
PMS-Ipratropium · DIN 02231245 · $1.3180
Teva-Ipratropium Sterinebs · DIN 02216221 · $1.3180
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since May 18, 2018 — choose a marketed DIN from the same-category list.